Multiple Arkansas bills target motor racing regulation
LITTLE ROCK, Ark. – A wild west of motor vehicle racing is getting plenty of attention from state lawmakers this session. From the race track to a tract of legislation. Both are asking where to accelerate or put on the brakes.
Currently, there are at least three bills that would regulate it. Track owners have gotten one withdrawn, asked for another's removal, and praised the third.
Malvern motocross complex aims to become national hub for sport
Jerry Bradley owns The Ridge Off-Road Park in Bradford. He convinced Rep. Wayne Long (Bradford-R) to withdraw House Bill 1564 Wednesday.
The legislation would have added a noise restriction, quiet hours, and liability insurance requirement to include all motocross, ATV tracks, truck or automobile racing tracks.
'ATV side-by-side motocross cycles I mean they use is just becoming extremely popular after Covid you know and I think that's why there's so many bills concerning the regulation of them,' Bradford said.
Homeowners around Diamond State Moto Complex near Malvern have been asking for restrictions for months. In December many, including Raymond Tanner, said it is unfair the business can disrupt their lives so easily.
'Tell me when do the people of the community not have the rights? Why do the people moving in making all the noise have a say so over us?' Tanner asked.
House Bill 1567 sponsored by Representative Rick McClure (Malvern (R)) is still in committee. It would apply the existing rural truck and automobile racing facilities code to ATV and motocross race facilities.
New permits would need to be issued with public notifications and hearings. That permit would need renewal each year and the county judge would weigh the benefits of the facility with the impact it has to property around it.
Sheridan 6-year-old taking passion for motocross racing nationwide, competing in amateur nationals
Diamond State Moto Complex has come out against it saying in part:
'A renewal process…could subject us to license revocation each year. If passed, these Bills will render operation of our facility and similar facilities across the state unfeasible and our investment in this community a total loss.'
The complex is in favor of House Bill 1465 sponsored by Representative Justin Gonzalez (Okolona (R)). It would recognize the inherent risk of participating in motocross and remove liability from the track owners in most cases of injury or death. Bradford would like to his that extend to parks like his.
'I think it all should be grouped into one you know one term that covers all of those that would that would simplify the law,' Bradford said.
Hopefully making the twists and turns more navigable for owners, racers, and neighbors.
'Because right now the way the laws are written is pretty complicated honestly,' Bradford explained.
Hot Spring County locals raise complaints with motocross complex
KARK 4 News contacted Long and McClure for comment. Neither responded as of the time of this report.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
10 minutes ago
- Yahoo
Ari Aster's ‘Eddington' Sharply Divides Cannes: Star Pedro Pascal Defends a Western About ‘Our Worst Fears' Amid Lockdown
When writer/director Ari Aster stood up for the ovation after the Cannes premiere of his divisive 2020-set Western 'Eddington' (July 16, A24), he said, 'I feel very privileged to be here. This is a dream come true. Thank you so much for having me. And, I don't know, sorry?' Indeed, festival attendees have been fiercely divided by his 145-minute portrait of a fictional New Mexico town wracked by COVID, BLM, ACAB, you-name-it-2020-buzz-concept during the darkest season of American lives in recent memory. Joaquin Phoenix (Aster's 'Beau Is Afraid') plays a conservative sheriff who decides to run against his Gavin Newsom-esque, pro-masks-and-testing adversary, Ted Garcia (Pedro Pascal), in the local mayoral election. More from IndieWire The Cannes 2025 Films So Far Most Likely to End Up in the Oscar Race 'Imago' Review: Chechen Documentary Explores a Filmmaker's Conflicted Return to His Roots Meanwhile, at home, Phoenix's character Joe Cross is in a quarantine bubble with his hysteria-addled wife Louise (Emma Stone) and her far-right conspiracy-obsessed mother Dawn (Deirdre O'Connell), the type for whom hydroxychloroquine was presumably a panacea. But Joe's campaign is all anti-masks, anti-vax, with the threat of cult leader Vernon Jefferson Peak (Austin Butler) also posing a challenge to his political and personal life. The film has sparked massive debates up and down the Croisette since premiering Friday night, with the starriest red carpet thus far and a press conference Saturday afternoon featuring Aster with his actors Phoenix, Pascal (in a sleeveless top), Stone (in a pixie haircut, her hair growing back presumably after shaving it off for Yorgos Lanthimos' upcoming 'Bugonia'), and Michael Ward, who plays Phoenix's next-in-command. IndieWire has talked to people who loved or hated the film, with rarely any opinion in between and certainly never without a strong response of some kind from anyone — whether out of boredom or raptures over Aster's in-your-face replay of our worst COVID-times memories. 'Eddington' could be a tough sell for audiences unwilling to be submersed again in summer 2020 and all the chaos and anxieties it erupted. Other pundits I've spoken to defend 'Eddington' as a necessary social satire that mocks and derides the panic of that year, while encapsulating it all into one movie as never before. IndieWire critic David Ehrlich wrote in his rave review that 'few other filmmakers would have the chutzpah required' to pull this movie off, 'and we should probably all be grateful that none of them have tried.' 'It's very scary to participate in a movie that speaks to issues like this,' Pascal said at the press conference. 'It's far too intimidating a question for me to address. I'm not informed enough. I want people to be safe and protective. I want very much to be on the right side of history.' 'Eddington' indeed takes shots at both sides of the aisle, roasting liberal posturing in the form of social justice youth like Sarah (Amélie Hoeferle), who posts TikToks about James Baldwin and rants about having any position at all on 'stolen land.' Phoenix's sheriff character, meanwhile, could only be wrought from the era of Trump, as he rails against mask mandates and is suspicious of the George Floyd-inspired protests shaking up his community. At one point, he swaggers into a grocery store with the pompousness of Western's most classic, gun-on-the-hip cowboys. Pascal added, 'I felt like [Aster] wrote something that was all our worst fears as that lockdown experience was already a fracturing society. This was building toward an untethered sense of reality. There is a point of not going back. I was overwhelmed by that fear, and it's wonderful that it was confirmed by Ari.' Aster, whose latest feature is a hairpin departure from the genre thrills and chills of films like 'Hereditary' and 'Midsommar' and is far from the spirit of intrusive-thought-induced weirdness of 'Beau Is Afraid,' added, 'I wrote this movie in a state of fear and anxiety. I wanted to try and pull back and show what it feels like to live in a world where nobody can agree on what is real anymore.' 'Eddington' is his first feature to premiere at Cannes. 'I feel like we're on a dangerous road, and we're living in an experiment that hasn't gone well,' Aster said (via Deadline) about his MAGA- and liberal-skewering Western. 'I feel there is no way out of it… Mass liberal democracies always had this fundamental agreement we agree what we're arguing about, that system was coming from power. So it's not like suddenly there's this bad power out there. It's always been there, but right now it's chaos.' Stone, who connected with Aster amid his 2024 'Beau Is Afraid,' said that her research into the conspiracy theories that turn her character against her husband even ended up modifying her personal social media algorithms (via Variety). 'The only additional thing that scared me a little bit in the algorithm system was looking into some of the things that are in this film that haven't been in my algorithm, unfortunately, added them to my algorithm,' she said. 'Because once you start Googling it, you start seeing more and more things. So it's a real rabbit hole, very quickly. Unfortunately, I'm still getting fed some crazy shit.' 'Eddington' is still the most conversation-starting Competition premiere at Cannes, with critics split over its social message and pacing (it's currently at 63 on Metacritic, where you can find reviews all over the map). How A24 will market this movie — only one teaser has been released so far, showing Phoenix doom-scrolling through familiar images of the deepest COVID era — is an intriguing question in the lead-up to its July theatrical release. Alex Garland's 'Civil War,' another post-COVID story of national conflict, did well for A24 last year, grossing more than $127 million by tapping into a fascination factor over a divided United States. Who will 'Eddington' appeal to? Either way, it's pitting Cannes audiences against each other — Screen Daily called it a 'wan satire,' while Variety deemed it 'brazenly provocative' — and will no doubt continue to stoke debate into the summer. Best of IndieWire Guillermo del Toro's Favorite Movies: 56 Films the Director Wants You to See 'Song of the South': 14 Things to Know About Disney's Most Controversial Movie The 55 Best LGBTQ Movies and TV Shows Streaming on Netflix Right Now
Yahoo
27 minutes ago
- Yahoo
Nika Pharmaceuticals, Inc. to Present at the Life Sciences Virtual Investor Forum June 11th-12th
Company invites individual and institutional investors, as well as advisors and analysts, to attend online at HENDERSON, Nev., June 10, 2025 (GLOBE NEWSWIRE) -- Nika Pharmaceuticals, Inc. (OTCQB:NIKA), based in Colorado, focused on cures for life-threatening diseases, today announced that Dimitar Savov, CEO, will present live at the Life Sciences Virtual Investor Frum hosted by on June 11th, 2025 DATE: June 11th TIME: 1:00 PM ETLINK: REGISTER HEREAvailable for 1x1 meetings: June 12th-17th between 09:00am ET and 11:30am ET This will be a live, interactive online event where investors are invited to ask the company questions in real-time. If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available after the event. It is recommended that online investors pre-register and run the online system check to expedite participation and receive event updates. Learn more about the event at Recent Company Highlights On May 19, 2025, NIKA published a market analysis for the countries of Ukraine, Syria, Jordan, Iraq, UAE, where NIKA has exclusive distribution agreements and has estimated a total of around €656 million in potential revenue. NIKA's partner company, Nika Europe, has made the second $195,554 payment for the vial production line and is currently finalizing the details of the clean rooms design in order to start construction. The production facility is expected to be completed in H2, 2025. On April 11, 2025, Nika Pharmaceuticals, Inc. published a report on the therapeutic effect and potential economic impact of ITV-1, which can be found here. On July 11, 2024 Nika Pharmaceuticals, Inc. signed an exclusive distribution agreement for the Republic of Nigeria. Under the terms, NIKA will receive €1,980 per each set of ITV-1 with two sets necessary for each treatment, which could result in €7.9 billion revenue. About Nika Pharmaceuticals, Inc. Nika Pharmaceuticals, Inc. (NIKA) is a pharmaceutical company, specializing in the treatment of HIV/AIDS, Hepatitis B and C, Rheumatoid Arthritis, Cancer, Diabetes, and all diseases, for which strengthened cell immunity is of vital importance. NIKA's intellectual property includes six drugs in injection form – two of which have successfully undergone clinical trials with good treatment results – four drugs in tablet form, and eleven dietary supplements. NIKA's goal is to not only achieve corporate profits, but to provide better and easier access to life-saving medicinal drugs and useful dietary supplements. Find more on Forward-looking Statement: This press release contains forward-looking statements. Certain statements, other than purely historical information, including estimates, projections, statements relating to our business plans, objectives, and expected operating results, and the assumptions upon which those statements are based, are 'forward- looking statements.' These forward-looking statements generally are identified by the words 'believes,' 'expects,' 'anticipates,'' estimates,' 'intends,' 'strategy,' 'plan,' 'may,' 'will,' 'would,' 'will be,' 'will continue,' 'will likely result,' and similar expressions. Forward-looking statements are based on current expectations and assumptions that are subject to risks and uncertainties which may cause actual results to differ materially from the forward-looking statements. Our ability to predict results or the actual effect of future plans or strategies is inherently uncertain. About Virtual Investor Conferences®Virtual Investor Conferences (VIC) is the leading proprietary investor conference series that provides an interactive forum for publicly traded companies to seamlessly present directly to investors. Providing a real-time investor engagement solution, VIC is specifically designed to offer companies more efficient investor access. Replicating the components of an on-site investor conference, VIC offers companies enhanced capabilities to connect with investors, schedule targeted one-on-one meetings and enhance their presentations with dynamic video content. Accelerating the next level of investor engagement, Virtual Investor Conferences delivers leading investor communications to a global network of retail and institutional investors. CONTACTS:Nika Pharmaceuticals, Clifford P. RedekopTitle Corporate SecretaryPhone (702) 326-3615 Email cliffredekop@ Virtual Investor Conferences John M. ViglottiSVP Corporate Services, Investor AccessOTC Markets Group (212) 220-2221johnv@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
32 minutes ago
- Business Wire
Guided Therapeutics Receives $700,000 Purchase Order and Initial Payment from New Chinese Distributor
PEACHTREE CORNERS, Ga.--(BUSINESS WIRE)--Guided Therapeutics, Inc. (OTCQB: GTHP), the maker of the LuViva Advanced Cervical Scan, announced today that it had received a purchase order and first payment from Hangzhou Dongye Medical Technology Company Ltd (HDMT) for 35 LuViva systems. HDMT will order directly from Guided Therapeutics and the devices will be assembled and tested by Guided Therapeutics' Chinese partner, Shandong Yaohua Medical Instrument Corporation (SMI). HDMT is in Hangzhou City, Zhejiang Province, where it is the exclusive gynecology products provider for 42 hospitals that perform approximately two million cervical cancer screenings annually. Said Yang Dongye, CEO of HDMT: 'We are extremely impressed with the performance of LuViva and our goal is to eventually replace the current screening tests with LuViva.' The purchase order for $700,000 is to supply HDMT with 35 systems over the next eight months starting in July of this year. 'We are extremely pleased to be working with HDMT to bring LuViva to Zhejiang Province and anticipate making initial shipments next month,' added Mark Faupel, Guided Therapeutics' CEO. 'Working directly with an exclusive provider of gynecology products that can potentially conduct two million LuViva tests each year is a major advance for GTI.' About Guided Therapeutics Guided Therapeutics, Inc. (OTCQB: GTHP) is the maker of a rapid and painless testing platform based on its patented biophotonic technology that utilizes light for the early detection of disease at the cellular level. The Company's first product is the LuViva® Advanced Cervical Scan, a non-invasive device used to detect cervical disease instantly and at the point of care. In a multi-center clinical trial with women at risk for cervical disease, the technology was able to detect cervical cancer up to two years earlier than conventional modalities, according to published reports. For more information, visit: The Guided Therapeutics LuViva ® Advanced Cervical Scan is an investigational device and is limited by federal law to investigational use in the U.S. LuViva, the wave logo and "Early detection, better outcomes" are registered trademarks owned by Guided Therapeutics, Inc. Forward-Looking Statements Disclaimer: A number of the matters and subject areas discussed in this news release that are not historical or current facts deal with potential future circumstances and developments. The discussion of such matters and subject areas is qualified by the inherent risks and uncertainties surrounding future expectations generally and also may materially differ from Guided Therapeutics' actual future experience involving any of or more of such matters and subject areas. Such risks and uncertainties include those related to the early stage of commercialization of products, the uncertainty of market acceptance of products, the uncertainty of development or effectiveness of distribution channels, the intense competition in the medical device industry, the sufficiency of capital raised in prior financings and the ability to realize their expected benefits, the uncertainty of future capital to develop products or continue as a going concern, the uncertainty of regulatory approval of products, and the dependence on licensed intellectual property, as well as those that are more fully described from time to time under the heading 'Risk Factors' in Guided Therapeutics' reports filed with the SEC, including Guided Therapeutics' Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and subsequent filings.
